X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs DISHMAN PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD DISHMAN PHARMA MERCK LTD/
DISHMAN PHARMA
 
P/E (TTM) x 46.4 25.1 184.8% View Chart
P/BV x 6.8 3.3 202.0% View Chart
Dividend Yield % 0.5 0.7 75.6%  

Financials

 MERCK LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-17
DISHMAN PHARMA
Mar-16
MERCK LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,358374 362.6%   
Low Rs933129 723.8%   
Sales per share (Unadj.) Rs665.0197.8 336.2%  
Earnings per share (Unadj.) Rs56.621.2 266.8%  
Cash flow per share (Unadj.) Rs72.534.7 208.7%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %1.30.8 164.8%  
Book value per share (Unadj.) Rs441.7179.9 245.5%  
Shares outstanding (eoy) m16.6080.69 20.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.3 135.4%   
Avg P/E ratio x20.211.9 170.6%  
P/CF ratio (eoy) x15.87.2 218.0%  
Price / Book Value ratio x2.61.4 185.3%  
Dividend payout %26.59.4 281.1%   
Avg Mkt Cap Rs m19,01120,306 93.6%   
No. of employees `0001.50.8 186.2%   
Total wages/salary Rs m1,6965,355 31.7%   
Avg. sales/employee Rs Th7,150.019,252.7 37.1%   
Avg. wages/employee Rs Th1,098.76,459.5 17.0%   
Avg. net profit/employee Rs Th608.22,064.1 29.5%   
INCOME DATA
Net Sales Rs m11,04015,961 69.2%  
Other income Rs m240265 90.3%   
Total revenues Rs m11,27916,226 69.5%   
Gross profit Rs m1,3764,103 33.5%  
Depreciation Rs m2641,091 24.2%   
Interest Rs m0944 0.0%   
Profit before tax Rs m1,3522,334 57.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m583624 93.5%   
Profit after tax Rs m9391,711 54.9%  
Gross profit margin %12.525.7 48.5%  
Effective tax rate %43.126.7 161.3%   
Net profit margin %8.510.7 79.3%  
BALANCE SHEET DATA
Current assets Rs m7,52311,018 68.3%   
Current liabilities Rs m2,2539,517 23.7%   
Net working cap to sales %47.79.4 507.7%  
Current ratio x3.31.2 288.5%  
Inventory Days Days52110 47.2%  
Debtors Days Days4135 116.4%  
Net fixed assets Rs m1,24016,304 7.6%   
Share capital Rs m166161 102.9%   
"Free" reserves Rs m7,16712,907 55.5%   
Net worth Rs m7,33314,516 50.5%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m9,91229,805 33.3%  
Interest coverage xNM3.5-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.5 208.0%   
Return on assets %9.58.9 106.3%  
Return on equity %12.811.8 108.6%  
Return on capital %20.817.5 118.4%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m1,0154,952 20.5%   
Fx outflow Rs m3,043697 436.7%   
Net fx Rs m-2,0284,255 -47.7%   
CASH FLOW
From Operations Rs m5372,786 19.3%  
From Investments Rs m-476-1,529 31.2%  
From Financial Activity Rs m-220-941 23.4%  
Net Cashflow Rs m-160316 -50.4%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 3.7 491.9%  
FIIs % 1.0 12.7 7.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 22.1 131.7%  
Shareholders   28,591 46,261 61.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Nov 15, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS